|
|
| |
Doxorubicin Hydrochloride Injection USP 50 mg |
| |
Ovarian carcinoma
Acute lymphoblastic leukemia
Acute myeloblastic leukemia
Wilm's tumor
Neuroblastoma
Soft tissue and bone sarcomas
Breast carcinoma
Hodgkin's disease
Malignant lymphoma
Bronchogenic carcinoma
Transitional cell bladder carcinoma
Thyroid carcinoma
Gastric carcinoma
|
| |
The common dosage schedule is 60-75 mg/m2 as a single intravenous injection administered every 3 weeks.
Alternative dosage schedule which has been reported to produce a lower incidence of congestive heart failure is a weekly dose of 20 mg/m2.
Another dose of 20-30 mg/m2 given daily for 3 days, repeated every 3-4 weeks has also been used.
Doxorubicin dose should be reduced in case of hyperbilirubinemia as
follows:
Plasma bilirubin
concentration
(mg/dL) |
: |
Dosage reduction
(%) |
| 1.2 - 3.0 |
: |
50 |
| 3.1 - 5.0 |
: |
75 |
Dosage Adjustment :
Renal Impairment : Not necessary.
Hepatic Impairment : Required. |
| |
Packing : |
10 Vials of 50 mg/25 ml |
|
|
